Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA: Bimatoprost SR vs SLT in Glaucoma or Ocular Hypertension
NCT02507687Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2015
- Primary completion
- Nov 2021
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost implant in Open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by AbbVie Inc. Primary endpoints: Change From Baseline in Intraocular Pressure at Week 4, Change From Baseline in Intraocular Pressure at Week 12 and 1 more. Started Aug 2015; status: completed.
02
Drugs
bimatoprost implant
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02507687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507687.